You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans

Authors

  • Victoire Cardot-Ruffino Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Immunology, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Naima Bollenrucher Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Luisa Delius Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • S Jennifer Wang Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Lauren K Brais Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Joshua Remland Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • C Elizabeth Keheler Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Keri M Sullivan Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Thomas A Abrams Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Leah H Biller Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Peter C Enzinger Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Nadine J McCleary Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Anuj K Patel Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Douglas A Rubinson Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Benjamin Schlechter Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Sarah Slater Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Matthew B Yurgelun Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • James M Cleary Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Kimberly Perez Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Michael Dougan Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Kimmie Ng Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Brian M Wolpin Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Harshabad Singh Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Stephanie K Dougan Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Immunology, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles

Citation

Cardot-Ruffino V, Bollenrucher N, Delius L, et al
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans
Journal for ImmunoTherapy of Cancer 2023;11:e006589. doi: 10.1136/jitc-2022-006589
Online issue publication 
June 21, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.